Vitestro Secures $70M Series B Funding to Advance Autonomous Blood Draw Technology

Why It Matters

Automating phlebotomy tackles chronic staffing shortages while improving test consistency, reshaping clinical workflows worldwide. Vitestro’s funding positions it as a front‑runner in medical robotics.

Key Takeaways

• $70M Series B fuels global rollout of autonomous phlebotomy
• Labcorp and Mayo Clinic back Vitestro’s robotic blood draw
• AI, infrared, ultrasound combine for vein detection
• Automation aims to cut staffing costs and variability
• Market sees robotics as solution to healthcare worker shortage

Pulse Analysis

Phlebotomy remains one of the most frequent procedures in modern medicine, with billions of blood samples collected annually. Yet the process is prone to human error, variable sample quality, and a growing strain on nursing staff. As hospitals grapple with staffing shortages and heightened demand for rapid diagnostics, the industry is actively seeking technologies that can standardize collection while freeing clinicians for higher‑value tasks.

Vitestro’s Aletta device tackles these challenges by fusing advanced imaging modalities—near‑infrared, ultrasound, and Doppler—with machine‑learning algorithms that map vein topology in real time. The robot autonomously aligns a needle, performs the draw, and secures the specimen, reducing variability and patient discomfort. Clinical validation has progressed to a proven concept stage, and the recent $70 million infusion, anchored by Labcorp and Mayo Clinic, provides the capital needed for regulatory submissions, manufacturing scale‑up, and entry into key international markets.

The broader market impact could be profound. Automated blood collection promises to alleviate the chronic shortage of skilled phlebotomists, lower per‑test labor costs, and improve data reliability for downstream diagnostics. As payers and providers prioritize efficiency, Vitestro’s technology may set a new standard for point‑of‑care sampling, prompting incumbents and startups alike to accelerate their own robotic solutions. Successful adoption could also catalyze further investment in AI‑driven procedural automation across the healthcare continuum.

Deal Summary

Vitestro announced a $70 million Series B round, backed by strategic and financial investors including Labcorp Venture Fund and Mayo Clinic. The funding will accelerate development of its autonomous robotic blood‑collection device and support global commercial expansion, highlighting growing interest in AI‑driven healthcare automation.